12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

AbbVie sales and marketing update

AbbVie launched Humira adalimumab in the U.K. to treat patients aged 6-17 years with severely active Crohn's disease who failed, are intolerant to or have contraindications to conventional therapy. The European Commission approved expanding the label of Humira for the indication...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >